M. Lelgemann

1.2k total citations · 1 hit paper
17 papers, 782 citations indexed

About

M. Lelgemann is a scholar working on Public Health, Environmental and Occupational Health, General Health Professions and Statistics, Probability and Uncertainty. According to data from OpenAlex, M. Lelgemann has authored 17 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Public Health, Environmental and Occupational Health, 6 papers in General Health Professions and 5 papers in Statistics, Probability and Uncertainty. Recurrent topics in M. Lelgemann's work include Clinical practice guidelines implementation (10 papers), Meta-analysis and systematic reviews (5 papers) and Health and Medical Studies (4 papers). M. Lelgemann is often cited by papers focused on Clinical practice guidelines implementation (10 papers), Meta-analysis and systematic reviews (5 papers) and Health and Medical Studies (4 papers). M. Lelgemann collaborates with scholars based in Germany, United Kingdom and United States. M. Lelgemann's co-authors include Bob Phillips, Gordon Guyatt, Elie A. Akl, Jean Bousquet, Pablo Alonso‐Coello, David M. Lang, Roman Jaeschke, Jan Brożek, Holger J. Schünemann and Anne Lethaby and has published in prestigious journals such as British Journal of Ophthalmology, Allergy and BMJ Quality & Safety.

In The Last Decade

M. Lelgemann

17 papers receiving 748 citations

Hit Papers

Grading quality of evidence and strength of recommendatio... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Grading quality of evidence and strength of recommendations in clinical practice guidelines
    2009 584 citations Jan Brożek, Elie A. Akl et al. Allergy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Lelgemann Germany 8 152 131 103 81 70 17 782
Belinda Udeh United States 16 101 0.7× 168 1.3× 77 0.7× 53 0.7× 79 1.1× 51 645
E Castelnuovo United Kingdom 14 115 0.8× 113 0.9× 116 1.1× 179 2.2× 85 1.2× 21 1.1k
Emilio Perea‐Milla Spain 20 205 1.3× 212 1.6× 77 0.7× 46 0.6× 41 0.6× 60 1.3k
Yoram Maaravi Israel 17 94 0.6× 83 0.6× 131 1.3× 62 0.8× 264 3.8× 37 949
Hiangkiat Tan United States 16 149 1.0× 242 1.8× 42 0.4× 100 1.2× 114 1.6× 62 1.2k
Molly McFadden United States 22 301 2.0× 285 2.2× 210 2.0× 93 1.1× 106 1.5× 65 1.4k
Medical Advisory Secretariat 20 75 0.5× 280 2.1× 65 0.6× 55 0.7× 74 1.1× 89 1.0k
Ofra Kalter‐Leibovici Israel 21 185 1.2× 125 1.0× 132 1.3× 28 0.3× 115 1.6× 66 1.3k
Bernard Cassou France 15 124 0.8× 146 1.1× 252 2.4× 62 0.8× 157 2.2× 54 1.1k
Douglas Badenoch United Kingdom 7 120 0.8× 109 0.8× 175 1.7× 54 0.7× 23 0.3× 13 609

Countries citing papers authored by M. Lelgemann

Since Specialization
Citations

This map shows the geographic impact of M. Lelgemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lelgemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lelgemann more than expected).

Fields of papers citing papers by M. Lelgemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lelgemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lelgemann. The network helps show where M. Lelgemann may publish in the future.

Co-authorship network of co-authors of M. Lelgemann

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lelgemann. A scholar is included among the top collaborators of M. Lelgemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lelgemann. M. Lelgemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Euler, U. S. von, Dirk Dahmann, Markus Follmann, et al.. (2013). S3-Leitlinie Gesundheitsüberwachung bei Beryllium-Exposition und diagnostisches Vorgehen bei berylliumassoziierter Erkrankung. DMW - Deutsche Medizinische Wochenschrift. 138(10). 488–492. 2 indexed citations
2.
Mustafa, Reem A., Wojtek Wiercioch, Jan Brożek, et al.. (2013). 076 Enhancing the Acceptance and Implementation of GRADE Summary Tables for Evidence about Diagnostic Tests. BMJ Quality & Safety. 22(Suppl 1). A36.3–A36. 1 indexed citations
3.
Schmucker, Christine, Yoon K. Loke, Christoph Ehlken, et al.. (2010). Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. British Journal of Ophthalmology. 95(3). 308–317. 57 indexed citations
4.
Brożek, Jan, Elie A. Akl, Pablo Alonso‐Coello, et al.. (2009). Grading quality of evidence and strength of recommendations in clinical practice guidelines. Allergy. 64(5). 669–677. 584 indexed citations breakdown →
5.
Lelgemann, M., et al.. (2008). Seltene Erkrankungen in professionellen Versorgungssystemen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 51(5). 509–518. 3 indexed citations
6.
Härter, Martin, M. Lelgemann, Susanne Weinbrenner, et al.. (2008). Entwicklung der S3- und Nationalen Versorgungs-Leitlinie Depression. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 51(4). 451–457. 15 indexed citations
7.
Ollenschläger, G., I. Kopp, M. Lelgemann, et al.. (2007). Das Programm für Nationale VersorgungsLeitlinien von BÄK, AWMF und KBV. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 50(3). 368–376. 6 indexed citations
8.
Schneider, M., M. Lelgemann, R. Kunz, et al.. (2007). Interdisziplinäre Leitlinie Management der frühen rheumatoiden Arthritis. Steinkopff eBooks. 35 indexed citations
9.
Lelgemann, M. & G. Ollenschläger. (2006). Evidenzbasierte Leitlinien und Behandlungspfade : Ergänzung oder Widerspruch?. Der Internist. 47(7). 690–698. 4 indexed citations
10.
Lelgemann, M., et al.. (2006). An e-learning platform for guideline implementation--evidence- and case-based knowledge translation via the Internet.. PubMed. 45(4). 389–96. 30 indexed citations
11.
Lelgemann, M. & G. Ollenschläger. (2006). Evidenzbasierte Leitlinien und Behandlungspfade. Der Internist. 47(7). 690–698. 10 indexed citations
12.
Vollmar, Horst Christian, et al.. (2006). Online-Fortbildung auf der Basis nationaler Versorgungsleitlinien. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 49(5). 412–417. 2 indexed citations
13.
Lelgemann, M. & G. Ollenschläger. (2006). [Evidence based guidelines and clinical pathways: complementation or contradiction?].. PubMed. 47(7). 690, 692–7. 12 indexed citations
14.
Lelgemann, M., Britta Lang, Regina Kunz, & Gerd Antes. (2005). Leitlinien. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 48(2). 215–220. 14 indexed citations
15.
Thöle, H., et al.. (2005). DELBI – Das Deutsche Leitlinien-Bewertungs-Instrument – Anforderungskatalog und Prüfinstrument in neuer Form. Das Gesundheitswesen. 67(7). 1 indexed citations
16.
Schneider, M., M. Lelgemann, Christoph Baerwald, et al.. (2004). Nutzen der station�ren Therapie in der Versorgung von Patienten mit Rheumatoider Arthritis. Zeitschrift für Rheumatologie. 63(5). 402–413. 5 indexed citations
17.
Kunz, Regina, M. Lelgemann, & Matthias Schneider. (2002). Evidenzbasierte Leitlinien - Wo stehen wir heute?. Zeitschrift für Rheumatologie. 61(0). 1–1. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Belinda Udeh Breakdown of academic impact, for papers by E Castelnuovo Breakdown of academic impact, for papers by Emilio Perea‐Milla Breakdown of academic impact, for papers by Yoram Maaravi Breakdown of academic impact, for papers by Hiangkiat Tan Breakdown of academic impact, for papers by Molly McFadden Breakdown of academic impact, for papers by Medical Advisory Secretariat Breakdown of academic impact, for papers by Ofra Kalter‐Leibovici Breakdown of academic impact, for papers by Bernard Cassou Breakdown of academic impact, for papers by Douglas Badenoch
Rankless by CCL
2026